Company profile: Lyra Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics for ear, nose, and throat diseases, including LYR-210 and LYR-220, bioabsorbable nasal mesh implants that deliver up to six months of continuous mometasone furoate for chronic rhinosinusitis, and the XTreo platform, a proprietary technology for direct, consistent, sustained drug delivery to affected tissues with a single administration.
Products and services
- XTreo™ platform: A proprietary technology platform engineered to deliver medicines directly and consistently to affected tissues for sustained periods with a single administration
- LYR-210: A bioabsorbable nasal mesh implant that delivers up to six months of continuous mometasone furoate therapy to the sinonasal passages for treating chronic rhinosinusitis (CRS)
- LYR-220: A larger bioabsorbable nasal mesh implant intended for CRS patients with post-surgical anatomy, delivering up to six months of continuous mometasone furoate drug therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lyra Therapeutics
Sedana Medical
HQ: Sweden
Website
- Description: Provider of anaesthetic delivery systems and agents, including the AnaConDa (Anaesthetic Conserving Device) for delivering anaesthetic agents during medical procedures; Sedaconda (isoflurane) for sedation with AnaConDa; Sedasource for continuous anaesthetic agent supply; and FlurAbsorb to absorb and manage anaesthetic gases in medical settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sedana Medical company profile →
Medical International Technology
HQ: Canada
Website
- Description: Provider of needle-free jet injectors for human and animal vaccinations, developing, marketing, and distributing these devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical International Technology company profile →
Cure Pharmaceutical
HQ: United States
Website
- Description: Provider of specialty pharmaceutical and bioscience drug formulation and delivery technologies, featuring the CUREfilm thin-film platform for sublingual and buccal delivery. Offerings include CUREfilm Blue (sildenafil for ED), oral thin-film insulin, CU-2025g for weight management, an oral Hepatitis B vaccine, and CUREfilm-based nutraceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cure Pharmaceutical company profile →
Vivani Medical
HQ: United States
Website
- Description: Provider of implantable visual prosthetics for blind individuals and developer of NanoPortal technology for miniature, subdermal drug implants delivering steady medication, including NPM-115 for chronic weight management and NPM-119 (under development) for type 2 diabetes; via subsidiary Cortigent, develops targeted neurostimulation for artificial vision and muscle movement restoration in stroke rehabilitation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivani Medical company profile →
Travanti Pharma
HQ: United States
Website
- Description: Provider of innovative drug delivery platforms that improve the safety, compliance, effectiveness, and ease of administration of medications delivered into the body; designs, develops, and markets these platforms to enhance medication delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Travanti Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lyra Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lyra Therapeutics
2.2 - Growth funds investing in similar companies to Lyra Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lyra Therapeutics
4.2 - Public trading comparable groups for Lyra Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →